{
    "clinical_study": {
        "@rank": "84190", 
        "brief_summary": {
            "textblock": "To evaluate safety and immune response in HIV-infected patients treated with multiple\n      injections of APL 400-003 vaccine.\n\n      PER 2/27/96 AMENDMENT: To evaluate the safety of the vaccine when administered via the\n      Biojector 2000 Needle-Free Injection Management System.\n\n      Facilitated DNA inoculation, a new type of DNA vaccine, involves direct injection of\n      non-infectious HIV genes into a patient's muscle, along with agents that promote uptake of\n      the genes into host cells. Host cells that have taken up these genes then produce viral\n      proteins in a form that elicits immune responses in the form of antibodies, killer T-cells,\n      and helper T-cells. The safety of this new vaccine approach needs to be assessed.\n\n      PER 2/27/96 AMENDMENT: The Biojector 2000 provides an option for delivering the vaccine\n      without a needle and employs a single-use syringe to avoid cross-contamination."
        }, 
        "brief_title": "A Phase I Trial of APL 400-003 Vaccine: Safety and Immune Response Evaluations of Multiple Injections at Escalating Doses in Asymptomatic HIV-Infected Patients", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "Facilitated DNA inoculation, a new type of DNA vaccine, involves direct injection of\n      non-infectious HIV genes into a patient's muscle, along with agents that promote uptake of\n      the genes into host cells. Host cells that have taken up these genes then produce viral\n      proteins in a form that elicits immune responses in the form of antibodies, killer T-cells,\n      and helper T-cells. The safety of this new vaccine approach needs to be assessed.\n\n      PER 2/27/96 AMENDMENT: The Biojector 2000 provides an option for delivering the vaccine\n      without a needle and employs a single-use syringe to avoid cross-contamination.\n\n      Patients are given intramuscular injections of APL 400-003 at one of three doses (30, 100,\n      or 300 mcg) on day 0 and again at weeks 10 and 20, and followed for 16 weeks after the final\n      dose. An 8-week period prior to initial dosing is required for immortalizing the patient's\n      PBMCs.\n\n      PER 2/27/96 AMENDMENT: Five patients will be evaluated at the 300 mcg dose with the\n      Biojector 2000."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Low doses of nonprescription NSAIDS, acetaminophen, ibuprofen, aspirin, replacement\n             hormone therapy, and vitamin supplements.\n\n        Patients must have:\n\n          -  Asymptomatic HIV infection with no acute related infection.\n\n          -  CD4 count >= 500 cells/mm3.\n\n          -  Normal hematologic, renal, hepatic, metabolic, and endocrine function.\n\n        NOTE:\n\n          -  No more than one patient over 50 years of age is permitted at each dose level.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Residual toxicity from prior drug treatment.\n\n          -  Hypersensitivity to bupivacaine or amide-type local anesthetic.\n\n          -  Active viral hepatitis, autoimmune disorders, or other debilitating chronic diseases.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Medications that affect immune function.\n\n          -  Antiretrovirals.\n\n        Patients with the following prior conditions are excluded:\n\n          -  Malignancies other than curatively treated basal cell or squamous cell carcinoma of\n             the skin or carcinoma in situ of the cervix.\n\n          -  History of anaphylaxis to vaccines.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Prior immunization with any experimental HIV vaccines.\n\n          -  Other experimental therapy within 30 days prior to study entry.\n\n          -  Prior cancer chemotherapy.\n\n          -  Antiretrovirals within 3 months prior to study entry.\n\n        Prior Treatment:\n\n        Excluded:\n\n          -  Prior radiotherapy. IV drug use or any other high-risk behavior."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "16", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002350", 
            "org_study_id": "089", 
            "secondary_id": "APL 400-003RX101"
        }, 
        "intervention": {
            "intervention_name": "APL 400-003", 
            "intervention_type": "Biological"
        }, 
        "keyword": [
            "Vaccines, Synthetic", 
            "AIDS Vaccines", 
            "DNA, Viral"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Philadelphia", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "19104"
                }, 
                "name": "Univ of Pennsylvania Med Ctr"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase I Trial of APL 400-003 Vaccine: Safety and Immune Response Evaluations of Multiple Injections at Escalating Doses in Asymptomatic HIV-Infected Patients", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "reference": [
            {
                "citation": "MacGregor RR, Gluckman S, Lacy K, Kaniefski B, Boyer J, Wang B, Bagarazzi M, William WV, Francher D, Ginsberg R, Higgins T, Weiner D. First human trial of a facilitated DNA plasmid vaccine for HIV-1: safety and host response. Int Conf AIDS. 1996 Jul 7-12;11(2):23 (abstract no WeB293)"
            }, 
            {
                "citation": "MacGregor R, Gluckman S, Lacy K, Wang B, Ugen K, Chattergoon M, Bagarazzi J, Williams W, Ginsberg R, Higgins T, Boyer J, Weiner D. A DNA plasmid vaccine for HIV-1: experience in the first human trial indicates humoral and cell-immune responses. Conf Retroviruses Opportunistic Infect. 1997 Jan 22-26;4th:142 (abstract no 421)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002350"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Apollon", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 1997"
    }, 
    "geocoordinates": {
        "Univ of Pennsylvania Med Ctr": "39.952 -75.164"
    }
}